AutDB features a modular framework that aims at collating multifactorial risk factors associated with autism spectrum disorder (ASD). The animal model (AM) module of AutDB was first developed for mouse models of genes and CNVs associated with ASD (Kumar et al., 2011).
Introduction
Animal models have been pivotal in understanding the etiology of many human diseases and determining effective therapeutic interventions (Smithies, 1993) . Research using animal models has unearthed mechanistic underpinnings and identified therapeutic targets for neurological disorders arising due to dysfunction of specific cell-types or brain regions, e.g., Parkinson's disease (Zeng et al., 2018) . Rodent models for diseases caused by viral or bacterial infections including some types of cancer and acquired immune deficiency syndrome (AIDS) have also led to an understanding of the fundamentals of the mammalian immune system leading to practical advances in healthcare management (Curwen and Wedge, 2009; von Bubnoff, 2008; Washington et al., 2013) . However, for complex behavioral disorders that have a more diffused pattern, with multiple and sporadic genomic loci implicated in disease development, rodent models have evoked more questions than answers, be it schizophrenia, Down syndrome or ASD (Chadman et al., 2012; O'Donnell, 2013; Victorino et al., 2017) .
AutDB has focused on curating and annotating ASD research for the past 10 years using a scientific annotation framework rooted in the biology of the disorder (Basu et al., 2009) The systematic annotation of autism-related data on a standardized platform has been an invaluable resource to researchers seeking to sort through confounding and ground-breaking findings.
Toward this end, ASD-associated AutDB gene and CNV datasets have been used widely by the research community to understand the genetic heterogeneity of ASD (Chen et al., 2018; Darnell et al., 2011; Krishnan et al., 2017) .
The Animal Model (AM) module of AutDB was created to add depth and precision to the annotation of ASD related models. The genetic models in AM are integrated with the corresponding gene in the human gene module of AutDB, providing human genetic evidence underlying each rodent model. Our database also includes various types of environmentally induced models for autism reported in the scientific literature. Several prenatal factors, including exposure to drugs (Smith and Brown, 2014) , role of paternal age (Kojima et al., 2018) and maternal immune factors circulating during gestation (Slawinski et al., 2018) are being studied as causative or modulatory inducers of ASD. Additionally, the complex effects of chemical exposure and drugs after birth are also undergoing scrutiny (Ali and Elgoly, 2013; Foley et al., 2015; Kalkbrenner et al., 2015; Laugeray et al., 2014; Li et al., 2018; Wagner et al., 2006) . In contrast to Mouse Genome Informatics (MGI), the paramount resource for mouse genetics for over 35 years, AutDB is a specialized resource that includes diverse types of ASD-related animal models, evidence or hypothesis-based, including inbred strains showing face-validity to Results
Representation of animal models in AutDB
AutDB is an open-access portal designed to provide a comprehensive view of risk factors associated with ASD. Adopting a systems biology approach, this resource integrates diverse functional information of ASD risk-factors while conserving their biological relationships. The AM module develops on the Human Gene and CNV modules of AutDB by including detailed phenotypic information of animal models. All genetic models are connected to the corresponding factor curated in AutDB for their relevance to ASD (Figure 1 ). The AM module catalogues induced models based on environmental risk factors and inbred strains with ASDconsistent phenotypes. Information regarding animal models is extracted from published, peerreviewed primary reports and parsed to provide a detailed view of the constructs and corresponding phenotypic data. The annotation of animal models is guided by a metadata repository of phenotypic terms (phenoterms) and experimental paradigms known as Phenobase (Kumar et al., 2011) . Phenoterms are systematically classified into 16 broad categories that align with human ASD phenotypic features (Figure 1b , Supplementary Table 1 ). Finally, AutDB integrates data from both mouse and rat models using a shared annotation framework for robust analysis.
Overview of data
The ASD rodent models described in this study were based on over 258 genes, 6 CNV regions, 72 inducers, and 9 inbred strains. These are referred to as 'ASD factors' henceforth. Initial analysis indicated that the mouse models were predominantly based on genetic factors, while rat models mainly comprised environmental inducers ( Supplementary Figure 1) . A wide variation in number of publications per ASD factor was also observed (Figure 2a ). The most annotated ASD factors (> 20 articles per factor) included the syndromic genes (Mecp2 and Fmr1) and the inbred strain (BTBR T+ Itpr3tf/J (BTBR)) in mouse (Figure 2a ) and valproic acid (VPA) in rat ( Figure 2b ). ASD models based on face validity such as inbred strain BTBR were among the highly annotated factors reflecting an intense focus of the research community. The next tier of annotation included high confidence ASD genes (Shank3, Chd8, Pten, Adnp), syndromic genes (Tsc1, Tsc2, Ube3a), recurrent CNVs (16p11.2, 22q11.2) and nongenetic factors (polyinosinic:polycytidylic acid (poly I:C) and VPA in mouse; lipopolysaccharide (LPS) in rat. Increasing evidence for nongenetic factors linked to ASD etiology, such as maternal immune activation (MIA) has propelled the development of such rodent models. Several mouse and rat models based on MIA induction by agents such as poly I:C, a viral mimetic, or LPS, a bacterial mimetic is represented prominently in the rodent dataset. Finally, a number of environmental factors with uncertain links to ASD such as citalopram, thalidomide, terbutaline, kainic acid, stress and maternal isolation also comprise the rat dataset ( Figure 2b ).
Signature data from ASD rodent models
To explore the data annotated in AutDB, which represents a comprehensive segment of research into ASD etiology, we analyzed the patterns in observations made in rodent models. In all, the data represents phenotypes of rodent models based on 345 ASD factors taken from 787 references. The frequency of phenoterm use across models is a measure of the validity of the phenoterm as a node of comparison. We determined the top 30 most frequently annotated phenoterms in AutDB are distributed across core, auxiliary and physiological categories ( Figure   3a ). Specifically, we find observed changes in 'General locomotor activity', 'Anxiety' and 'Social interaction' as the three most frequent phenoterms annotated in AutDB.
In our annotation, phenoterms are paired with a qualitative value term or "phenovalue" to indicate the direction of change compared to control animals. Phenovalues for ASD models can be 'Increased ', 'Decreased', 'Abnormal' or 'No Change' . This is a key feature for building the phenotypic profile of ASD models reported in hundreds of scientific reports. We mapped the percentage distribution of phenovalues for the 30 most frequently used phenoterms ( Figure 3b ). Phenoterms in core categories showed higher incidence of ASD-consistent measures of phenovalue: 'Ultrasonic vocalization' (Decreased = 45%; Increased = 15%), 'Social memory' (Decreased = 66%), 'Social interaction' (Decreased = 54%), 'Social approach' (Decreased = 59%), 'Self-grooming' (Increased = 54%) and 'Repetitive digging' (Decreased = 17%; Increased = 42%). However, in 14 out of the 30 phenoterms, 'No Change' accounted for more than 50% of the annotation for that phenoterm. These mostly represent standard control measures conducted in disease models to assess the validity of more complex behavioral tasks. For example, animals may be tested in 'Startle response' prior to testing 'Cued or contextual fear conditioning'. Some of the most frequently used phenoterms from auxiliary categories are also routinely tested in various disease models of neurodevelopmental disorders, like 'Spatial learning'. The phenoterms from physiological categories are frequently tested in rodent ASD models with variable outcomes. Interestingly, the phenoterms 'Synaptic plasticity' and 'Synaptic transmission' are reported as 'Decreased' 39% and 42% of the time, respectively, reflecting a heterogeneous contribution of ASD factors towards synaptic function.
Rescue models
In AutDB, rescue models originate from established ASD models (genetic, induced or inbred) undergoing a treatment protocol with the aim of alleviating one or more ASD related symptoms.
A rescue paradigm is defined based on a unique combination of rescue agent, dosage and timing of treatment. Rescue agents are further categorized according to the type of intervention (Supplementary Table 2 ). In some cases, rescue models provide an understanding of mechanisms underlying ASD related phenotypes whereas in other studies rescue models employs pharmaceutical agents (e.g., FDA approved memantine and rapamycin) to establish or validate their therapeutic use ASD patients.
As noted before, genetic models comprise the most frequently annotated entities in AutDB ( Figure 2) . Additionally, the majority of rescue paradigms tested on genetic models of ASD are based on pharmaceutical interventions (Figure 4a ). Therefore, we focused on this dataset comprising a total of 123 pharmaceutical agents that were identified in various rescue paradigms in AutDB. We further identified 24 drugs used in more than one paradigm indicating the prevalent credence in their putative role in ASD therapy (Figure 4b) . Notably, in the list of 32 genes obtained using this prioritization, 10 are key ASD genes with multiple lines of human genetic evidence (SFARI categories 1-2), three are well-known syndromic genes, 8 are genes with suggestive evidence (category 3), and 11 are lower scoring or functional genes where the link to ASD is not fully established from human genetic evidence ( Supplementary Table 3 ). The correlation between the pharmaceutical rescue agents and the targeted ASD rodent models are shown in figure 4b. Given the importance of altered E:I ratio in ASD (Rubenstein and Merzenich, 2003) , several drugs based on the common molecular substrate of glutamate receptors (N-methyl D-aspartate (NMDA) or metabotropic (mGluR) were tested on multiple genetic models of ASD ( Supplementary Table 4 ). Interestingly, three different drugs functioning as agonists for gamma aminobutyric acid receptor subunit A (GABA-a) rescued ASD-related symptoms in multiple models arising from important ASD genes (SHANK2, SCN1A, GABRB3, GRIN1, UBE3A, ARHGAP32). Some of the other frequently tested drugs (fluoxetine, memantine, 2-methyl-6-(phenylethynyl)pyridine (MPEP), lithium) are currently prescribed for psychiatric disorders However, a small subset of drugs was only tested on models based on a single gene: JQ1 and FRAX48 in Fmr1 models; NAP in Adnp models; and p-cofilin in Shank3 models. In these cases, the drugs targeted specific pathways regulated by the ASD gene. For example, JQ1 is an inhibitor of bromo and extra terminal domain (BET) proteins that are regulated by fragile-X mental retardation protein (FMRP).
Case Study: Shank3
While studying the overall phenotypes in a large set of ASD models provided an overview of ASD literature and trends in research, an in-depth analysis of an important ASD-linked genetic factor, Shank3, illustrates the functionality of the intricate annotation in AutDB. Shank3, a multidomain scaffolding protein with a prominent role in glutamatergic synapses has been implicated in ASD through the identification of rare damaging mutations in multiple studies (high confidence SFARI Gene). Accordingly, several research groups have reported mouse models of Shank3 in an attempt to define its contributory role in ASD. However, the complex structure of the Shank3 gene with multiple exons and experimentally validated alternative splicing from intragenic promoters presented a major challenge in establishing relevant animal models. The regions targeted in mouse models that are annotated in AutDB are shown in Figure 5a . Overall, there are 27 loss-of-function (LOF) models of Shank3 including 15 knockout (KO) and 10 knockin (KI) mouse models together with two KO rat models ( Supplementary Table 8 and 9 for details on domains targeted and model constructs). Targeting these protein domains in Shank3 resulted in different sets of isoforms being lost, further adding to the resultant phenotypic complexity (Monteiro and Feng, 2017; Wang et al., 2014) . Unlike many ASD genes essential for survival (Ji et al., 2016) , homozygous (HM) loss of Shank3 is compatible with life through developmental stages to adulthood in both mouse and rat. Consequently, a broad range of assays targeting ASD-related core and associated phenotypes were performed in various Shank3 models ( Supplementary Figure 2) . The most frequently assessed phenotypes in Shank3 mouse models were similar to the overall phenotype reporting trends in the entire set of ASD models in AutDB ( Supplementary Table 5 ). Both 'Anxiety' and 'Self-grooming' were increased in all tested HM KO mouse models ( Figure 5b) indicating a strong recapitulation of human ASD phenotypes in Shank3 KOs. Similar in essence to the allelic heterogeneity in human ASD phenotypes (Leblond et al., 2014) a wide variability of phenotypes in Shank3 KO models was observed based on the targeted domain. Surprisingly, full-length KOs displayed normal social behavior whereas some deficits in social behavior were seen in models targeting ANK, PDZ, and PRO regions. Ultrasonic vocalization (USV), another 'core' phenotype postulated to assay for communicative behavior, was also variably affected in the different Shank3 models, with full-length and ANK targeted models displaying impairments in USV calls while models with mutated PDZ domains showed normal USV phenotype.
Dendritic spine density in the brain, another aberrant phenotype in ASD patients, was found to be anomalous in all HM Shank3 KO mutants (Figure 5b ; AutDB). An expanded view of the top 5 'core' phenoterms indicates that not all phenotypes have been tested in individual constructs.
Interestingly, Shank3 heterozygous (HT) mutants manifest some ASD phenotypes indicating that dosage and nature of knocked-out Shank3 isoforms are essential for normal function (supplementary figures 3, 4 and 5). Two human mutations in exon 21 have also been recreated in Shank3 KI models the ASD related InsG and the Schizophrenia (Schz) related R1117X (Speed et al., 2015; Zhou et al., 2016) . As shown in Figure 6 , compared to exon 21 KO mutants, the KI mutants have similar changes in anxiety and the InsG KI mutants also show similar changes in synaptic transmission to the KOs. Observations from rat models of Shank3, recently added to the AM module indicate that rats and mice display differential changes in behavioral phenotypes (Supplementary Figure 6 ).
While several rescue paradigms have been tested on Shank3 models, they were all based on eight LOF models. A genetic approach based on reinstatement of wildtype Shank3 expression after birth resulted in alleviation of a subset of ASD phenotypes ( Supplementary Table 6 ).
Pharmaceutical agents like MPEP, TG003, p-cofilin and CDPPB (3-cyano-N-(1,3-diphenyl-1Hpyrazol-5-yl) benzamide), have been used in different Shank3 models (Table 1) . High doses of p-cofilin, TG003, and MPEP restored or ameliorated repetitive self-grooming seen in the Shank3 mutants. Interestingly, p-cofilin and TG003 also normalize social behavior with a sustained effect ( Supplementary Table 7 ). Rescue attempts on rat Shank3 models have in turn utilized oxytocin, which restored some deficits in social behavior and reward reinforced choice behavior (Table 2 ). Furthermore, neuroreceptor activity and synaptic neuroreceptor based transmission were restored in ANK and PRO domain targeted Shank3 mutants treated with p-cofilin and IGF-1. In the rat Shank3 model, synaptic plasticity is found to be completely restored in the medial prefrontal cortex and partially restored in the hippocampus following intracranial injection of oxytocin, indicating an avenue for translational studies.
Discussion
AutDB is a platform designed to be a specific resource where the AM module focuses on the indepth annotation of genetic and non-genetic ASD models, using multiple layers of standardized vocabulary encapsulated in the phenobase. Therefore, our database encompasses models based on high confidence ASD genes (e.g., Chd8, Shank3), environmental inducers (e.g., VPA, MIA via exposure to viruses or viral mimetics like polyI:C) and inbred strains (e.g., BTBR). Rat models of ASD were recently added to AutDB to exploit interspecies conserved biology in investigating genetic and environmental ASD risk factors, also believed to be the best approach in the success of clinical trials. Additionally, rats are used in more studies assessing the effects of inducers, thereby increasing our repertoire of inducers tested in rodent ASD models. As the exact genetic signature of ASDs still remains to be determined and is a field of intense ongoing research, we believe that including putative and established models that represent characteristics of autism will lead to a more comprehensive understanding of this complex disorder.
At the time of data freeze for this article (March 2018), AutDB included rodent models based on 258 genes linked to ASD, linked to our Human Gene module providing details of all rare and common variants in these genes identified in affected individuals. In contrast, mouse models based on only 57 genes have been linked to ASD in MGI (August 2018). In addition to providing ASD-specific genetic relevance to the animal models, a number of features distinguish our annotation model from MGI. First, our integrative approach includes genetic and nongenetic models of ASD within a single platform. Second, a standardized phenotypic repository (Phenobase) structured according to the diagnostic symptoms of ASD guides annotation of all 1 0 animal models in AutDB. Third, we make dedicated provisions for all the confounding details that can give rise to contradictory data and uphold robust findings. AutDB provides distinct information on the experimental paradigms used to assess a phenotype and relevant experimental details specific to studies, information that is not available in MGI. One of the primary confounders is the experimental paradigm used to assess a phenotype, e.g., anxiety can be assessed in as many as five to six direct testing protocols, including open-field test, lightdark exploration, elevated plus maze and novelty-induced hypophagia (Bailey, 2009), while being reported as auxiliary observations from several other protocols like Morris water-maze, social behavior testing etc. (Larrieu et al., 2017; Schulz et al., 2007) . As noted in results, anxiety is one of the most frequently assessed phenotypes in ASD models as well.
In our unique rescue model dataset, we highlight test outcomes from experimental drugs, FDA approved drugs, behavioral interventions, and transplantations of remedial cells or microbes, on rodent models of ASD. We also curate genetic manipulations that have been used to rescue ASD related phenotypes. Genetic, behavioral or transplantation-based rescue paradigms play an important role in understanding the contribution of different factors for the development of phenotypes in ASD, even if not all of them can be translated into human interventions. We aim to curate new technologies as their use in ASD research is increasing, however, caveats in their application emerge retrospectively, e.g., clozapine-N-oxide (CNO) used to activate designer receptors exclusively activated by designer drugs (DREADDs) is reverse metabolized clozapine (interestingly a drug tested in ASD models) in rodents and is not pharmacologically inert (Manvich et al., 2018) . Therefore, it is of great interest to the scientific community to combine the time-tested standard tasks and sophisticated frontier technology to unveil interesting relationships between different types of behavior.
The rescue model dataset of AutDB offers a comprehensive resource for translational studies.
For example, genetic rescues on Shank3 models of ASD (see Supplementary Table 6 ) indicate the crucial role of normal Shank3 expression through adulthood, indicating the importance of these Shank3 mutant lines in testing remedial approaches for Shank3 mutations during postnatal development and adulthood (Mei et al., 2016) . A faster and cost-effective route for new clinical therapy in ASD is the use of existing pharmaceutical agents, or "repurposing" of drugs already approved by FDA for other conditions. As seen in Figure 4 several known drugs have been tested in genetic models, including rapamycin, fluoxetine, clozapine and risperidone.
Rescue treatment paradigms and effects, annotated discretely for rescue models in AutDB with a new set of controlled vocabulary distinct from parent ASD models, are as important as the 1 1 drugs used for rescue as dosage and length of treatment can significantly change the outcome in rodents and people. This is evident in the Shank3 rescue models where a drug, p-cofilin, tailored to act on a deficit specifically manifested in Shank3 mutants: dendritic spine formation displayed differences in outcome in low (0.15 picomol/g) versus high (15picomol/g) doses.
Some of the drugs tested in Shank3 models have also been tested in other mouse models of ASD: CDPPB has been used in rescue paradigms to treat Shank2 mutants leading to normalization of social interaction (Won et al., 2012) .
Translation from preclinical to clinical studies requires rigorous testing of a large number of paradigms, with changes in dosage and route of administration requiring. While not reported as often as favorable effects, presence of adverse effects of drug treatments are noted in AutDB and could play an important role towards clinical drug trials. We believe refractory phenotypes should be reported whenever testing is conducted, so that the community can benefit from the knowledge and reduce unnecessary waste of resources. From the Shank3 dataset itself, it is surprising that the assessments for perseverative self-grooming and social approach or interaction were not reported after several treatments (Table 1) . Overcoming this 'positive data bias' is the basis for our comprehensive annotation of the 'No Change' phenotype which indicates the absence of ASD related phenotype or no statistical difference from control measures. A single model for ASD will likely not emerge from rodent studies for this genetically and clinically heterogeneous disorder. Similarly, it is unlikely that there will be a single drug prescribed for ASD therapy. As presented here, a number of the most frequent ASD related phenotypes, like social behavior and anxiety, are assessed in Shank3 models. Additionally, based on the scaffolding function of the Shank3 at the synapse, other phenotypes like synaptic plasticity, glutamate neuroreceptor levels and more detailed neurophysiology are also reported. This is where the advantage of rodent models lie: in deciphering the constellation of phenotypes that group together. For example, a recent study using optogenetics indicates that spatial learning can have direct effects on social behavior (Murugan et al., 2017) and it is likely that future research from different fields will enhance the existing knowledge on ASD biology with new insights. Our database is primed to curate new types of paradigms and knit together robust, The validity of an animal model is based on its relevance to ASD. The articles must describe animal models that are based on evidence from association studies in humans, or, alternatively, models that display strong face validity for ASD-consistent endophenotypes. An animal model
where an ASD-associated factor is manipulated to assess resulting phenotypes is an evidencebased model, while a model showing ASD-consistent endophenotypes for a factor with no association with ASD is a hypothesis-based model. We attempt to build a comprehensive dataset for rodent models based on high confidence ASD genes and prioritize reports containing detailed phenotypic data on those. Additionally, rescue models are annotated based on rescue paradigms where an agent or intervention is used to alleviate a phenotype in an ASD animal model. We categorize these rescue paradigms based on the type of agent:
transplantation-based, procedural, behavioral, genetic or pharmaceutical. We have developed annotation methods to clearly represent the treatment effects on ASD phenotypes paralleled in rodent models.
The data freeze date for all data shown in this article is March 31, 2018.
Phenobase: dynamic hierarchical phenotypic metadata
The individual phenotypes observed in ASD models are annotated using controlled vocabulary ('phenoterms') and organized into 16 broad categories in a resource termed as the Phenobase (Supplemental Table 1 ).These categories are grouped as 'core' where the comprising phenoterms closely parallel ASD core phenotypes, 'auxiliary' when the parallel human ASD phenotypes are not core diagnostic features of ASD, or 'physiological' for most other associated phenotypes that are routinely assessed to determine biological underpinnings of ASD.
Phenoterms, which are arranged in a hierarchical manner, are based on endophenotypes observed in rodent models. As many complex endophenotypes of rodent animals are being reported, we have added phenoterms that capture specificity while still rooted in a broader term, such that broad terms at the top of the hierarchy are separated by colons from specific terms.
For example, the term 'Morphology of the basal ganglia: Striatum: Caudoputamen' specifies the morphological changes to the caudoputamen, a part of the striatum, which in turn is a part of the basal ganglia. Our phenoterms are intended to capture complex as well as simple endophenotypes that are physiological, robust or quantitative and conserved between species.
It should be noted here that the phenoterms have been developed in the context of curated ASD literature, therefore they reflect the phenotypes assessed in ASD rodent models and not the full complexity and scope of a category per se.
In addition to phenoterms, the Phenobase contains a standardized list of experimental paradigms. This list is a discrete part of the database that is used to represent the tests used to study phenotypes in different animal models. The standardization of experimental paradigms adapts a uniform nomenclature that circumvents the variety of synonyms used in literature for similar experimental set-ups. The Phenobase catalogues over 450 experimental paradigms that map to the whole set of 620 phenoterms. The combined use of phenoterm and experimental paradigm provides a more comprehensive picture of observations made by authors, which allows for better comparisons of model phenotypes between different ASD models as well as between researchers.
Data analysis and visualization
Most data analysis and frequency measurements were conducted in R using packages:
'tidyverse', 'dplyr' and 'forcats' (Wickham, 2014) . Graphics were developed with ggplot2 or in excel (Wickham, 2016) .
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Tables and Figures
The type of the ASD-associated factors is shown by distinct outline colors: gene (red), CNV (pink), induced (blue), and inbred (green). Note that only factors that have four or more references are shown in the mouse (A) and two or more references are shown in rat (B).
Abbreviations: VPA, valproic acid; Poly I:C, polyinosinic:polycytidylic acid; APA, advanced paternal age; PPA, propionic acid; LPS, lipopolysaccharide; FRAb, folate receptor antibody;
FAST, seizure-prone rat. Only agents that were tested in more than one rescue paradigm are shown. 'n' refers to the number of treatment paradigms tested on models based on the same gene. This figure depicts that several core phenotypes are exhibited by HT and HM models and shows the presence of apparently contradictory data in behavioral analyses, which in some instances can be explained due to differences in age or sex of animals tested (see main text). 
